Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 5,106 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 5,106 shares of Maze Therapeutics stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $26.47, for a total value of $135,155.82. Following the sale, the chief marketing officer directly owned 14,894 shares of the company’s stock, valued at $394,244.18. This represents a 25.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Harold Bernstein also recently made the following trade(s):

• On Thursday, September 3rd, Harold Bernstein sold 5,189 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total transaction of $134,965.89.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total transaction of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Stock Performance

NASDAQ MAZE opened at $26.21 on Friday. The firm has a 50-day moving average price of $28.69 and a two-hundred day moving average price of $31.17. Maze Therapeutics, Inc. has a 12-month low of $14.27 and a 12-month high of $53.65. The company has a market capitalization of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). Analysts anticipate that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. ARCH Venture Management LLC bought a new position in shares of Maze Therapeutics in the 2nd quarter valued at $122,983,582. Alphabet Inc. acquired a new position in shares of Maze Therapeutics during the 2nd quarter worth $41,435,000. TRV GP IV LLC bought a new stake in shares of Maze Therapeutics during the 2nd quarter worth $133,502,907. Spruce Street Capital LP acquired a new stake in Maze Therapeutics in the first quarter valued at about $5,970,000. Finally, Boothbay Fund Management LLC boosted its stake in Maze Therapeutics by 16.3% in the fourth quarter. Boothbay Fund Management LLC now owns 409,372 shares of the company’s stock valued at $16,960,000 after buying an additional 57,497 shares in the last quarter.

Key Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on MAZE shares. BTIG Research reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, August 12th. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Finally, Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Maze Therapeutics presently has a consensus rating of “Buy” and an average target price of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.